Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Lenz L, Neff C, Solimeno C, Cogan ES, Abramson VG, Boughey JC, Falkson C, Goetz MP, Ford JM, Gradishar WJ, Jankowitz RC, Kaklamani VG, Marcom PK, Richardson AL, Storniolo AM, Tung NM, Vinayak S, Hodgson DR, Lai Z, Dearden S, Hennessy BT, Mayer EL, Mills GB, Slavin TP, Gutin A, Connolly RM, Telli ML, Stearns V, Lanchbury JS, Timms KM. Lenz L, et al. Breast Cancer Res Treat. 2023 Nov;202(1):191-201. doi: 10.1007/s10549-023-07046-3. Epub 2023 Aug 17. Breast Cancer Res Treat. 2023. PMID: 37589839 Free PMC article.
Hereditary cancer risk assessment and genetic testing in the community urology practice setting.
Shore ND, Lenz L, Cogan ES, Iliev D, Spencer L, Flake DD 2nd, Meek S, Davis T, Copeland K, Finch R, Schiff W, Korman H, Rao M, Belkoff L, Jalkut M, Mariados N, D'Anna R, Mehlhaff B, Slavin TP, Cohen TD. Shore ND, et al. Among authors: lenz l. Prostate. 2022 May;82(7):850-857. doi: 10.1002/pros.24327. Epub 2022 Mar 3. Prostate. 2022. PMID: 35239202
Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing.
Lenz L, Clegg W, Iliev D, Kasten CR, Korman H, Morgan TM, Hafron J, DeHaan A, Olsson C, Tutrone RF Jr, Richardson T, Cline K, Yonover PM, Jasper J, Cohen T, Finch R, Slavin TP Jr, Gutin A. Lenz L, et al. Prostate Cancer Prostatic Dis. 2024 Sep 5. doi: 10.1038/s41391-024-00888-y. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 39237680
Cell Cycle Progression Score, but Not Phosphatase and Tensin Homolog Loss, Is an Independent Prognostic Factor for Metastasis in Intermediate- and High-risk Prostate Cancer in Men Treated With and Without Salvage Radiotherapy.
Trock BJ, Jing Y, Mabey B, Sangale Z, Lenz L, Haney N, Vidal I, Glavaris SA, Guner G, Ertunc O, Kulac I, Baena Del Valle JA, Jones T, Han M, Partin AW, Cohen T, Stone S, De Marzo AM. Trock BJ, et al. Among authors: lenz l. J Urol. 2022 Dec;208(6):1182-1193. doi: 10.1097/JU.0000000000002922. Epub 2022 Aug 25. J Urol. 2022. PMID: 36006048
Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer.
Morris DS, Woods JS, Edwards B, Lenz L, Logan J, Flake DD, Mabey B, Bishoff JT, Cohen T, Stone S. Morris DS, et al. Among authors: lenz l. Urol Oncol. 2021 Jun;39(6):366.e19-366.e28. doi: 10.1016/j.urolonc.2020.11.016. Epub 2020 Nov 27. Urol Oncol. 2021. PMID: 33257218 Free article.
Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy.
Tward JD, Schlomm T, Bardot S, Canter DJ, Scroggins T, Freedland SJ, Lenz L, Flake DD 2nd, Cohen T, Brawer MK, Stone S, Bishoff J. Tward JD, et al. Among authors: lenz l. Clin Genitourin Cancer. 2021 Aug;19(4):296-304.e3. doi: 10.1016/j.clgc.2021.01.003. Epub 2021 Jan 19. Clin Genitourin Cancer. 2021. PMID: 33608228 Free article.
The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation.
Tward J, Lenz L, Flake DD II,, Rajamani S, Yonover P, Olsson C, Kapoor DA, Mantz C, Liauw SL, Antic T, Fabrizio M, Salzstein D, Shore N, Albertson D, Henderson J, Lee SP, Gay HA, Michalski J, Hung A, Raben D, Garraway I, Lewis MS, Nguyen PL, Marshall DT, Brawer MK, Stone S, Cohen T. Tward J, et al. Among authors: lenz l. Int J Radiat Oncol Biol Phys. 2022 May 1;113(1):66-76. doi: 10.1016/j.ijrobp.2021.09.034. Epub 2021 Oct 3. Int J Radiat Oncol Biol Phys. 2022. PMID: 34610388 Free article.
Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy.
Cuzick JM, Stone S, Lenz L, Flake DD, Rajamani S, Moller H, Berney DM, Cohen T, Scardino PT. Cuzick JM, et al. Among authors: lenz l. Cancer Rep (Hoboken). 2022 Aug;5(8):e1535. doi: 10.1002/cnr2.1535. Epub 2021 Aug 22. Cancer Rep (Hoboken). 2022. PMID: 34423592 Free PMC article.
158 results